SELLAS Life Sciences Group, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Angelos Stergiou
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Times Square Tower New York City NY United States of America 10036
- IPO Date
- Mar 12, 2008
- CIK
- 0001390478
- Website
- sellaslifesciences.com
- Similar Companies
- Business
- SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company specializing in the development of novel therapeutics for a broad range of cancer indications. The company's main product candidates include galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms Tumor 1 (WT1) protein, which is implicated in various hematologic malignancies and solid tumors, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor with potential applications in acute myeloid leukemia (AML) and other myeloid diseases. SELLAS develops these therapies with a focus on oncology and immunotherapy, leveraging strategic collaborations with institutions like Memorial Sloan Kettering Cancer Center for licensing and development purposes. The company operates primarily in the United States with extensible global licensing arrangements. Founded in 2012 and headquartered in New York City, SELLAS has recently advanced its clinical pipeline with significant clinical trial progress, including continued development of SLS009 with expected trial enrollment in early 2026. The company executed a $31 million warrant exercise with an institutional investor in late 2025, bolstering its financial position to support ongoing operations. SELLAS also partnered with WEP Clinical to launch an Expanded Access Program for galinpepimut-S to support patients during the ongoing pivotal REGAL Phase 3 clinical trial in AML. These operational moves reflect the company’s strategic emphasis on late-stage clinical development and commercialization readiness in oncology therapeutics. SELLAS Life Sciences engages in multiple collaborations and licenses, including an exclusive global license from Memorial Sloan Kettering Cancer Center for its WT1-targeting cancer immunotherapy. The company is also advancing its CDK9 inhibitor licensed from GenFleet Therapeutics for global markets outside Greater China. Its products are positioned for use as monotherapy or in combination with other therapies for a variety of hematologic cancers and solid tumors, targeting patient populations with high unmet medical needs. The firm’s pipeline development is supported by strong clinical data signals and regulatory incentives such as the FDA Rare Pediatric Disease Designation for pediatric AML treatment. In summary, SELLAS Life Sciences Group develops innovative immunotherapeutic and small molecule oncology drugs, focusing on WT1-targeted therapy and CDK9 inhibition. Its recent key developments include clinical trial progress for SLS009, expanded access for GPS, a significant capital raise through warrant exercises, and ongoing scientific and commercial partnerships aimed at advancing late-stage cancer drug candidates toward market approval and commercialization. This description reflects SELLAS Life Sciences Group’s comprehensive focus on oncology biopharmaceuticals, recent clinical advancements, collaborations, and financial strengthening as of late 2025.
SELLAS Life Sciences Stock Is Surging Wednesday: What's Driving The Move?
SELLAS Life Sciences to Participate in Upcoming Investor Conferences
SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Sellas Life Sciences: 'Hold' As Phase 3 AML Study Progresses To Key Event
Wall Street Analysts Think SELLAS Life Sciences Group, Inc. (SLS) Could Surge 66.09%: Read This Before Placing a Bet
All You Need to Know About SELLAS Life Sciences Group, Inc. (SLS) Rating Upgrade to Buy
Wall Street Analysts Believe SELLAS Life Sciences Group, Inc. (SLS) Could Rally 63.58%: Here's is How to Trade
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up on Earnings Beat
SELLAS Stock Up 346% in a Year as Cancer Vaccine Trial Nears Its Final 8 Deaths
SELLAS Life Sciences Group (NASDAQ:SLS) & Dianthus Therapeutics (NASDAQ:DNTH) Critical Survey
SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update
SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference
SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009
What's Going With SELLAS Life Sciences Stock On Wednesday?
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)
Solaris Resources (TSE:SLS) Reaches New 52-Week High – Should You Buy?
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Up – What’s Next?